Bank of America’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-76,500
Closed -$3.14M 8313
2021
Q3
$3.14M Buy
+76,500
New +$4.19M ﹤0.01% 4023
2021
Q1
Sell
-17,100
Closed -$1.2M 7494
2020
Q4
$1.2M Buy
+17,100
New +$702K ﹤0.01% 4354
2018
Q2
Sell
-704,200
Closed -$23.3M 7128
2018
Q1
$23.3M Buy
+704,200
New +$25.1M ﹤0.01% 1640

Other funds holding EDIT

Bank of America's EDIT Position: Q1 2026 in Review

Bank of America reduced its Editas Medicine (EDIT) stake by 30% in Q1 2026, selling an estimated $124K and leaving 134,866 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #5102.

Bank of America first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $13.7M in Q2 2021. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Bank of America held 134,866 shares of Editas Medicine worth $333K as of Q1 2026.
  • Bank of America sold 58,809 Editas Medicine shares in Q1 2026, an estimated $124K.
  • Editas Medicine made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5102 holding.
  • Bank of America first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Bank of America's Editas Medicine position peaked at $13.7M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.